• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Dime Bancorp

Dime Bancorp

  1. EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME )

    EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema ( DME )

  2. ABILITY Network Appoints New Chief Financial Officer

    ABILITY Network Appoints New Chief Financial Officer

  3. EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME )

    EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema ( DME )

  4. Regeneron Reports Second Quarter 2014 Financial and Operating Results

    Regeneron Reports Second Quarter 2014 Financial and Operating Results

  5. Genentech Submits Supplemental Biologics License Application to FDA for Lucentis Indication in Diabetic Retinopathy

    Genentech Submits Supplemental Biologics License Application to FDA for Lucentis Indication in Diabetic Retinopathy

  6. pSivida Announces ILUVIEN® Receives Marketing Authorization in Norway and Approval for Reimbursement in Portugal

    pSivida Announces ILUVIEN® Receives Marketing Authorization in Norway and Approval for Reimbursement in Portugal

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.